BioSpace News Archive

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that two abstracts with data in multiple myeloma have been accepted by the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. One of the abstracts relates to the pivotal phase 2 HORIZON study evaluating melflufen in relapsed refractory multiple myeloma (RRMM) patients. The a

The Risk Management Association has made available a guide entitled “SARS-CoV-2 Principles of Workforce Return to Facilities” that addresses the questions, scenarios, and challenges confronting financial institutions as they transition work-from-home employees back to offices and branches.

A new double-blind, placebo-controlled study published in the Journal of Nutrients found that supplementation with Robuvit®, a powerful antioxidant extract derived from French oak wood, improves general health, mood and social functioning of patients within four weeks of a surgical procedure.

Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, announced today that it has entered into a licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of “Remdesivir” for the treatment of Covid-19

The Supervisory Board of Sartorius AG approved the Executive Board’s recommendation to submit a proposal to the Annual General Shareholders’ Meeting, which is now a virtual meeting scheduled for June 26, 2020, to pay dividends of 0.36 euro per preference share and 0.35 euro per ordinary share.

Roivant Sciences today announced several updates for its adaptive, randomized, double-blind, placebo-controlled, multi-center pivotal BREATHE trial evaluating the impact of intravenous (IV) treatment with gimsilumab on mortality in COVID-19 patients with lung injury or ARDS.

LifeX Labs is now offering wet laboratory space to grow Southwestern Pennsylvania’s life sciences ecosystem.

The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group today announce the positive first interim results of the multicenter randomized open comparative clinical trial of the drug Favipiravir on patients hospitalized with COVID-19.

Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, announced its financial results for the first quarter ended March 31, 2020.

Brickell Biotech, Inc., a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.